This article is more than 5 years old. Information may no longer be current.
LEO Pharma, KLOX Tech to develop BioPhotonic acne treatment platform
Click Here to Manage Email Alerts
LEO Pharma and KLOX Technologies announced they have entered into a worldwide license and joint venture agreement to further the development and marketing of KLOX’s BioPhotonic dermatology technology platform.
The CE-approved acne treatment uses a non-abrasive, non-thermal multi-LED light in conjunction with a photoactivable converter gel. The platform targets the underlying problems that lead to acne, and also stimulates collagen synthesis and healing in traumatized skin. Treatment takes 15 minutes and is recommended twice per week for 6 weeks, according to a press release.
The agreement, which excludes Canada, establishes the likelihood for future collaboration between the companies in developing new dermatological treatments from KLOX’s BioPhotonic technology.
Under the agreement, LEO Pharma will be responsible for clinical and commercial activities, including manufacturing. The company will also provide financial funding support to KLOX for dermatology research and product development, according to the press release.